Deferred Income Tax Expense (Benefit) of Vanda Pharmaceuticals Inc. from 31 Dec 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Vanda Pharmaceuticals Inc. annual and quarterly Deferred Income Tax Expense (Benefit) in USD history and change rate from 31 Dec 2010 to 31 Dec 2025.
  • Vanda Pharmaceuticals Inc. Deferred Income Tax Expense (Benefit) for the quarter ending 31 Mar 2025 was $7,797,000, a 3070% decline year-over-year.
  • Vanda Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2025 was $81,443,000.
  • Vanda Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was $6,482,000, a 404% decline from 2023.
  • Vanda Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $1,286,000, a 214% decline from 2022.
Source SEC data
View on sec.gov
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Change (%)
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Change (%)

Vanda Pharmaceuticals Inc. Annual Deferred Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $81,443,000 +$87,925,000 01 Jan 2025 31 Dec 2025 10-K 12 Feb 2026 2025 FY
2024 $6,482,000 -$5,196,000 -404% 01 Jan 2024 31 Dec 2024 10-K 12 Feb 2026 2025 FY
2023 $1,286,000 -$2,416,000 -214% 01 Jan 2023 31 Dec 2023 10-K 12 Feb 2026 2025 FY
2022 $1,130,000 -$5,615,000 -83% 01 Jan 2022 31 Dec 2022 10-K 14 Feb 2025 2024 FY
2021 $6,745,000 +$556,000 +9% 01 Jan 2021 31 Dec 2021 10-K 08 Feb 2024 2023 FY
2020 $6,189,000 +$93,956,000 01 Jan 2020 31 Dec 2020 10-K 09 Feb 2023 2022 FY
2019 $87,767,000 -$87,767,000 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
2018 $0 $0 01 Jan 2018 31 Dec 2018 10-K 11 Feb 2021 2020 FY
2017 $0 +$104,000 01 Jan 2017 31 Dec 2017 10-K 26 Feb 2020 2019 FY
2016 $104,000 01 Jan 2016 31 Dec 2016 10-K 17 Feb 2017 2016 FY
2011 $1,821,000 +$3,642,000 01 Jan 2011 31 Dec 2011 10-K 25 Feb 2014 2013 FY
2010 $1,821,000 01 Jan 2010 31 Dec 2010 10-K 26 Feb 2013 2012 FY

Vanda Pharmaceuticals Inc. Quarterly Deferred Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $7,797,000 -$7,551,000 -3070% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q1 2024 $246,000 -$2,260,000 -112% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q1 2023 $2,014,000 -$2,403,000 -54% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q1 2022 $4,417,000 +$3,257,000 +281% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q1 2021 $1,160,000 +$281,000 +32% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q1 2020 $879,000 +$879,000 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q1 2019 $0 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.